Your browser doesn't support javascript.
loading
Successful A2 to O Simultaneous Liver and Kidney Transplantation in the Setting of Pre-operative Positive HLA Crossmatch: A Case Report.
Vigneshwar, Mythili; Sambommatsu, Yuzuru; Gupta, Gaurav; Philogene, Mary Carmelle; Bruno, David A.
Afiliación
  • Vigneshwar M; School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
  • Sambommatsu Y; Department of Surgery, Division of Transplant Surgery, Hume- Lee Transplant Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia. Electronic address: Yuzuru.Sambommatsu@vcuhealth.org.
  • Gupta G; Department of Internal Medicine, Division of Nephrology, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
  • Philogene MC; Department of Surgery, Division of Transplant Surgery, Hume- Lee Transplant Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
  • Bruno DA; Department of Surgery, Division of Transplant Surgery, Hume- Lee Transplant Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Transplant Proc ; 2024 Jul 13.
Article en En | MEDLINE | ID: mdl-39004578
ABSTRACT
Simultaneous liver and kidney transplantation (SLKT) is possible for patients with high donor-specific HLA antibodies or with A2 donors to O recipients with high A2 titers. We report the first case of SLKT in a highly sensitized O recipient with organs from an A2 donor. The recipient is a 59-year-old woman with chronic kidney disease and liver failure due to autoimmune hepatitis and drug-induced liver injury. Immune work-up 8 days pre-transplant demonstrated a negative crossmatch and no HLA antibody (calculated panel reactive antibodies = 0%). Anti-A2 IgG levels were 512. The donor was a deceased 24-year-old man. One day before transplantation, serum from the recipient showed a significant increase in antibody reactivity (calculated panel reactive antibodies = 100%) attributable to blood product transfusion and memory response from previous pregnancies. Consequently, a crossmatch was positive for T and B cells with two newly detected HLA antibodies against the donor's antigens. On the day of surgery, the liver was transplanted first. Six hours and 37 minutes later, a repeat flow crossmatch was negative; donor-specific antibodies (DSAs) fell below the positive threshold, and anti-A2 IgG titer fell to 256. Thus, the kidney was transplanted after basiliximab induction therapy. Seven days post-transplant, non-donor-specific HLA antibodies were present but DSAs remain negative. The patient was discharged on postoperative day 57 with no signs of rejection at 4 months. This case illustrates a rapid and prolonged reduction in antibody titers (HLA and ABO) after SLKT. SLKT is feasible in patients with both DSA and high anti-A2 titer.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Transplant Proc Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Transplant Proc Año: 2024 Tipo del documento: Article